Spinal Cord Diseases D013118

Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Spinal Cord Diseases

Description

Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.   MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Subtype Terms (14)

Amyotrophic Lateral Sclerosis
216 drugs (96 approved, 120 experimental)

Epidural Abscess
 

Muscular Atrophy, Spinal
28 drugs (18 approved, 10 experimental)

Myelitis
5 drugs (4 approved, 1 experimental)

Pneumorrhachis
 

Spinal Cord Compression
5 drugs (3 approved, 2 experimental)

Spinal Cord Injuries
179 drugs (96 approved, 83 experimental)

Spinal Cord Neoplasms
15 drugs (10 approved, 5 experimental)

Spinal Cord Vascular Diseases
 

Spinocerebellar Degenerations
5 drugs (2 approved, 3 experimental)

Stiff-Person Syndrome
14 drugs (12 approved, 2 experimental)

Subacute Combined Degeneration
 

Syringomyelia
1 approved drug

Tabes Dorsalis
 


Approved Indicated Drugs (3)

baclofen (lioresal)

cyclobenzaprine (flexeril)

iohexol (Omnipaque)

Phase 4 Indicated Drugs (3)

oxybutynin (ditropan)

sevoflurane (ultane)

solifenacin (vesicare)

Phase 3 Indicated Drugs (4)

ibudilast

methylprednisolone (medrol)

pregabalin (lyrica)

s-methionine

Phase 2 Indicated Drugs (7)

finasteride (Proscar)

gadobutrol (gadavist)

gadoversetamide (optimark)

interferon beta-1b (betaseron)

sodium phenylbutyrate (buphenyl)

testosterone (delatestryl)

Ursodoxicoltaurine


Organization Involved with Phase 4 Indications (8)

Astellas

CSL Behring

Icahn School of Medicine at Mount Sinai

Katholieke Universiteit Leuven

Ohio State University

Pfizer

Singapore General Hospital

University of Roma La Sapienza

Organization Involved with Phase 3 Indications (18)

AO Foundation

Department of Veteran Affairs

Kyowa Hakko Kirin

Medical Research Council

Mundipharma

National Institute of Neurological Disorders and Stroke (NINDS)

National Institute on Drug Abuse (NIDA)

Rush University

Seoul National University

St. Marianna University School of Medicine

University of Birmingham

University of California, Davis

University of California, San Diego

University of Cambridge

University of London

University of Michigan

University of Toronto

University of Washington

Organization Involved with Phase 2 Indications (9)

ALS Association

ALS Finding a Cure Foundation

Amylyx Pharmaceuticals Inc.

Bayer

Harvard University

Leandro P. Rizzuto Foundation

Northeast ALS Consortium

North Florida Foundation for Research and Education

University of Florida

Organization Involved with Phase 1 Indications (2)

Fujian Medical University

Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Organization Involved with Other Experimental Indications (4)

Rockefeller University

University Hospital Pierre Zobda-Quitman

University of Martinique

Yodakubo Hospital

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.